An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential

An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential

Background-Doxorubicin (DOXO) is an effective anthracycline chemotherapeutic, but its use is limited by cumulative dose-dependent cardiotoxicity. Neuregulin-1β is an ErbB receptor family ligand that is effective against DOXO-induced cardiomyopathy in experimental models but is also proneoplastic. We...

Full description

Bibliographic Details
Main Authors: Jay, Steven M. (Contributor), Murthy, Ashwin C. (Author), Hawkins, Jessica F. (Author), Wortzel, Joshua R. (Author), Steinhauser, Matthew L. (Author), Alvarez, Luis M. (Contributor), Gannon, Joseph (Author), Macrae, Calum A. (Author), Griffith, Linda G. (Contributor), Lee, Richard T. (Author)
Other Authors: Massachusetts Institute of Technology. Center for Gynepathology Research (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor)
Format: Article
Language:English
Published: American Heart Association, 2014-08-21T18:47:12Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items